Loading
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Previous close
$3.23
+$0.15 · +4.87%
Regular session · ET · Market data may be delayed.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Day range
Current $3.23
52-week range
Current $3.23
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
60
Fair Value
Sentiment
42
Mixed
Risk
67
High Risk
Momentum
69
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Day range
Current $3.23
52-week range
Current $3.23
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 40.52M USD | 32.31M USD | 78.12M USD | 19.71M USD | 25.54M USD |
| Cost of goods sold | — | 199.25M USD | 6.06M USD | 6.34M USD | 5.05M USD |
| Gross profit | 40.52M USD | −166.93M USD | 72.06M USD | 13.38M USD | 20.49M USD |
| Research and development | 89.95M USD | 199.25M USD | 177.65M USD | 174.96M USD | 142.51M USD |
| Selling, general, and administrative | 49.9M USD | 71.99M USD | 69.65M USD | 70.7M USD | 76.18M USD |
| Operating expenses | 139.86M USD | 84.22M USD | 241.24M USD | 239.33M USD | 213.64M USD |
| Interest income | 8.31M USD | 14.06M USD | 17.57M USD | 5.52M USD | 607K USD |
| Interest expense | 6.17M USD | — | — | — | — |
| Depreciation and amortization | 5.28M USD | 5.81M USD | 6.06M USD | 6.34M USD | 5.05M USD |
| Operating income | −99.34M USD | −251.15M USD | −169.18M USD | −225.95M USD | −193.15M USD |
| Net income | −160.06M USD | −237.09M USD | −153.22M USD | −220.43M USD | −192.5M USD |
Company facts updated Sep 5, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI12.62M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM7.97M0.01%79.88B USD0.19%$296.01+0.28%
iShares Biotechnology ETFIBB3.23M0.03%10.72B USD0.44%$211.92-0.88%
Vanguard Extended Market ETFVXF2.96M0.00%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Growth ETFIWO2.57M0.02%14.58B USD0.24%$377.54+0.12%
Schwab U.S. Small-Cap ETFSCHA1.47M0.01%22.56B USD0.03%$34.55+1.01%
Vanguard Russell 2000 ETFVTWO1.45M0.01%17.4B USD0.06%$119.62+0.25%
Vanguard Health Care ETFVHT1.2M0.01%20.9B USD0.09%$321.66-0.97%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMiShares Biotechnology ETFIBBVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOVanguard Health Care ETFVHTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
